Premium
In vivo Imaging and Drug Storage by Quantum‐Dot‐Conjugated Carbon Nanotubes
Author(s) -
Guo Yan,
Shi Donglu,
Cho Hoonsung,
Dong Zhongyun,
Kulkarni Amit,
Pauletti Giovanni M.,
Wang Wei,
Lian Jie,
Liu Wen,
Ren Lei,
Zhang Qiqing,
Liu Guokui,
Huth Christopher,
Wang Lumin,
Ewing Rodney C.
Publication year - 2008
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.200800406
Subject(s) - materials science , plga , carbon nanotube , conjugated system , in vivo , drug delivery , quantum dot , nanotechnology , nanoparticle , surface modification , chemical engineering , polymer , composite material , microbiology and biotechnology , engineering , biology
Abstract A specially designed carbon nanotube (CNT) is developed for use in the early detection and treatment of cancer. The key functionalities for biomedical diagnosis and drug delivery are incorporated into the CNTs. In vivo imaging of live mice is achieved by intravenously injecting quantum dot (QD)‐conjugated CNT for the first time. With near infrared emission around 752 nm, the CNT with surface‐conjugated QD (CNT‐QD) exhibit a strong luminescence for non‐invasive optical in vivo imaging. CNT surface modification is achieved by a plasma polymerization approach that deposited ultra‐thin acrylic acid or poly(lactic‐ co ‐glycolic acid) (PLGA) films (∼3 nm) onto the nanotubes. The anticancer agent paclitaxel is loaded at 112.5 ± 5.8 µg mg −1 to PLGA‐coated CNT. Cytotoxicity of this novel drug delivery system is evaluated in vitro using PC‐3MM2 human prostate carcinoma cells and quantified by the 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay. The in vivo distribution determined by inductively coupled plasma mass spectrometry (ICP‐MS) indicates CNT‐QD uptake in various organs of live animals.